Martin K, Barbieri R. Treatment of menopausal symptoms with hormone therapy. Available at: https://www.uptodate.com/contents/treatment-of-menopausal-symptoms-with-hormone-therapy. Accessed August 10, 2017.
Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 2012;104:386–405.
Nishiyama T, Kanazawa S, Watanabe R et al.. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. Int J Urol 2004;11:735–741.
Chandwani KD, Heckler CE, Mohile SG et al.. Hot flashes severity, complementary and alternative medicine use, and self-rated health in women with breast cancer. Explore (NY) 2014;10:241–247.
Chang HY, Jotwani AC, Lai YH et al.. Hot flashes in breast cancer survivors: frequency, severity and impact. Breast 2016;27:116–121.
Leining MG, Gelber S, Rosenberg R et al.. Menopausal-type symptoms in young breast cancer survivors. Ann Oncol 2006;17:1777–1782.
Charig CR, Rundle JS. Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma. Urology 1989;33:175–178.
Freedland SJ, Eastham J, Shore N. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer Prostatic Dis 2009;12:333–338.
Sarosdy MF, Schellhammer PF, Soloway MS et al.. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int 1999;83:801–806.
Schow DA, Renfer LG, Rozanski TA, Thompson IM. Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J 1998;91:855–857.
Walker LM, Tran S, Robinson JW. Luteinizing hormone–releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects. Clin Genitourin Cancer 2013;11:375–384.
Autorino R, Perdona S, D'Armiento M et al.. Gynecomastia in patients with prostate cancer: update on treatment options. Prostate Cancer Prostatic Dis 2006;9:109–114.
Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718–1729.
De Bruin ML, Huisbrink J, Hauptmann M et al.. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood 2008;111:101–108.
Goodwin PJ, Ennis M, Pritchard KI et al.. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365–2370.
Skinner R, Mulder RL, Kremer LC et al.. Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. Lancet Oncol 2017;18:e75–90.
- Search Google Scholar
- Export Citation
. Skinner R Mulder RL Kremer LC Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. Lancet Oncol 2017; 18: e75– 90.
Krekow LK, Hellerstedt BA, Collea RP et al.. Incidence and predictive factors for recovery of ovarian function in amenorrheic women in their 40s treated with letrozole. J Clin Oncol 2016;34:1594–1600.
Su HI, Sammel MD, Green J et al.. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer 2010;116:592–599.
Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 2015;22:1155–1172.
Drewe J, Bucher KA, Zahner C. A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. Springerplus 2015;4:65.
Johns C, Seav SM, Dominick SA et al.. Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions. Breast Cancer Res Treat 2016;156:415–426.
Rada G, Capurro D, Pantoja T et al.. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 2010:CD004923.
Joffe H, Guthrie KA, LaCroix AZ et al.. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med 2014;174:1058–1066.
Kelsberg G, Maragh L, Safranek S. Clinical inquiry: which nonhormonal treatments are effective for hot flashes? J Fam Pract 2016;65:E1–3.
Simon JA, Portman DJ, Kaunitz AM et al.. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause 2013;20:1027–1035.
Barton DL, Loprinzi CL, Novotny P et al.. Pilot evaluation of citalopram for the relief of hot flashes. J Support Oncol 2003;1:47–51.
Capriglione S, Plotti F, Montera R et al.. Role of paroxetine in the management of hot flashes in gynecological cancer survivors: results of the first randomized single-center controlled trial. Gynecol Oncol 2016;143:584–588.
Carpenter JS, Storniolo AM, Johns S et al.. Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist 2007;12:124–135.
Biglia N, Bounous VE, Susini T et al.. Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors. Eur J Cancer Care (Engl) 2016, doi: 10.1111/ecc.12484.
Kimmick GG, Lovato J, McQuellon R et al.. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 2006;12:114–122.
Loprinzi CL, Pisansky TM, Fonseca R et al.. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998;16:2377–2381.
Loprinzi CL, Sloan JA, Perez EA et al.. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578–1583.
Wu MF, Hilsenbeck SG, Tham YL et al.. The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer. Breast Cancer Res Treat 2009;118:369–375.
Ramaswami R, Villarreal MD, Pitta DM et al.. Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 2015;152:231–237.
Shams T, Firwana B, Habib F et al.. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med 2014;29:204–213.
Haque R, Shi J, Schottinger JE et al.. Tamoxifen and antidepressant drug interaction in a cohort of 16,887 breast cancer survivors. J Natl Cancer Inst 2016;108:djv337.
Kelly CM, Juurlink DN, Gomes T et al.. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010;340:c693. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20142325.
Butt DA, Lock M, Lewis JE et al.. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause 2008;15:310–318.
Yurcheshen ME, Guttuso T Jr, McDermott M et al.. Effects of gabapentin on sleep in menopausal women with hot flashes as measured by a Pittsburgh Sleep Quality Index factor scoring model. J Womens Health (Larchmt) 2009;18:1355–1360.
Reddy SY, Warner H, Guttuso T Jr et al.. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006;108:41–48.
Loprinzi CL, Qin R, Balcueva EP et al.. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol 2010;28:641–647.
Pandya KJ, Morrow GR, Roscoe JA et al.. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005;366:818–824.
Bordeleau L, Pritchard KI, Loprinzi CL et al.. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 2010;28:5147–5152.
Laufer LR, Erlik Y, Meldrum DR, Judd HL. Effect of clonidine on hot flashes in postmenopausal women. Obstet Gynecol 1982;60:583–586.
Nagamani M, Kelver ME, Smith ER. Treatment of menopausal hot flashes with transdermal administration of clonidine. Am J Obstet Gynecol 1987;156:561–565.
Pandya KJ, Raubertas RF, Flynn PJ et al.. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000;132:788–793.
- Search Google Scholar
- Export Citation
. Pandya KJ Raubertas RF Flynn PJ Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000; 132: 788– 793.
Goldberg RM, Loprinzi CL, O'Fallon JR et al.. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994;12:155–158.
Loibl S, Schwedler K, von Minckwitz G et al.. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients—a double-blind, randomized study. Ann Oncol 2007;18:689–693.
Buijs C, Mom CH, Willemse PH et al.. Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat 2009;115:573–580.
Boekhout AH, Vincent AD, Dalesio OB et al.. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2011;29:3862–3868.
Cramer H, Rabsilber S, Lauche R et al.. Yoga and meditation for menopausal symptoms in breast cancer survivors—a randomized controlled trial. Cancer 2015;121:2175–2184.
Elkins G, Marcus J, Stearns V et al.. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol 2008;26:5022–5026.
Kroenke CH, Caan BJ, Stefanick ML et al.. Effects of a dietary intervention and weight change on vasomotor symptoms in the Women's Health Initiative. Menopause 2012;19:980–988.
Caan BJ, Emond JA, Su HI et al.. Effect of postdiagnosis weight change on hot flash status among early-stage breast cancer survivors. J Clin Oncol 2012;30:1492–1497.
Stefanopoulou E, Grunfeld EA. Mind-body interventions for vasomotor symptoms in healthy menopausal women and breast cancer survivors. A systematic review. J Psychosom Obstet Gynaecol 2017;38:210–225.
Su HI, Sammel MD, Springer E et al.. Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors. Breast Cancer Res Treat 2010;124:205–211.
Franco OH, Chowdhury R, Troup J et al.. Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis. JAMA 2016;315:2554–2563.
Quella SK, Loprinzi CL, Barton DL et al.. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group trial. J Clin Oncol 2000;18:1068–1074.
Taku K, Melby MK, Kronenberg F et al.. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials. Menopause 2012;19:776–790.
Thomas AJ, Ismail R, Taylor-Swanson L et al.. Effects of isoflavones and amino acid therapies for hot flashes and co-occurring symptoms during the menopausal transition and early postmenopause: a systematic review. Maturitas 2014;78:263–276.
Van Patten CL, Olivotto IA, Chambers GK et al.. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol 2002;20:1449–1455.
MacGregor CA, Canney PA, Patterson G et al.. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur J Cancer 2005;41:708–714.
Sharma P, Wisniewski A, Braga-Basaria M et al.. Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. J Urol 2009;182:2265–2272.
Chen WY, Giobbie-Hurder A, Gantman K et al.. A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. Breast Cancer Res Treat 2014;145:381–388.
Laakmann E, Grajecki D, Doege K et al.. Efficacy of Cimicifuga racemosa, Hypericum perforatum and Agnus castus in the treatment of climacteric complaints: a systematic review. Gynecol Endocrinol 2012;28:703–709.
Jacobson JS, Troxel AB, Evans J et al.. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001;19:2739–2745.
Pockaj BA, Gallagher JG, Loprinzi CL et al.. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol 2006;24:2836–2841.
Garland SN, Xie SX, Li Q et al.. Comparative effectiveness of electro-acupuncture versus gabapentin for sleep disturbances in breast cancer survivors with hot flashes: a randomized trial. Menopause 2017;24:517–523.
Lesi G, Razzini G, Musti MA et al.. Acupuncture as an integrative approach for the treatment of hot flashes in women with breast cancer: a prospective multicenter randomized controlled trial (AcCliMaT). J Clin Oncol 2016;34:1795–1802.
Walker EM, Rodriguez AI, Kohn B et al.. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol 2010;28:634–640.
Mao JJ, Bowman MA, Xie SX et al.. Electroacupuncture versus gabapentin for hot flashes among breast cancer survivors: a randomized placebo-controlled trial. J Clin Oncol 2015;33:3615–3620.
Reed SD, Guthrie KA, Newton KM et al.. Menopausal quality of life: RCT of yoga, exercise, and omega-3 supplements. Am J Obstet Gynecol 2014;210:244.e1–11.
Newton KM, Reed SD, Guthrie KA et al.. Efficacy of yoga for vasomotor symptoms: a randomized controlled trial. Menopause 2014;21:339–346.
Aiello EJ, Yasui Y, Tworoger SS et al.. Effect of a yearlong, moderate-intensity exercise intervention on the occurrence and severity of menopause symptoms in postmenopausal women. Menopause 2004;11:382–388.
Daley AJ, Thomas A, Roalfe AK et al.. The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial. BJOG 2015;122:565–575.
Daley A, Stokes-Lampard H, Thomas A, MacArthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2014;11:CD006108.
Lindh-Astrand L, Nedstrand E, Wyon Y, Hammar M. Vasomotor symptoms and quality of life in previously sedentary postmenopausal women randomised to physical activity or estrogen therapy. Maturitas 2004;48:97–105.
Sternfeld B, Guthrie KA, Ensrud KE et al.. Efficacy of exercise for menopausal symptoms: a randomized controlled trial. Menopause 2014;21:330–338.
Sternfeld B, Dugan S. Physical activity and health during the menopausal transition. Obstet Gynecol Clin North Am 2011;38:537–566.
Ueda M. A 12-week structured education and exercise program improved climacteric symptoms in middle-aged women. J Physiol Anthropol Appl Human Sci 2004;23:143–148.
Duijts SF, van Beurden M, Oldenburg HS et al.. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol 2012;30:4124–4133.
- Search Google Scholar
- Export Citation
. Duijts SF van Beurden M Oldenburg HS Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol 2012; 30: 4124– 4133.
Smith RL, Flaws JA, Gallicchio L. Does quitting smoking decrease the risk of midlife hot flashes? A longitudinal analysis. Maturitas 2015;82:123–127.
Peppone LJ, Mustian KM, Morrow GR et al.. The effect of cigarette smoking on cancer treatment-related side effects. Oncologist 2011;16:1784–1792.
Gallicchio L, Miller SR, Kiefer J et al.. Risk factors for hot flashes among women undergoing the menopausal transition: baseline results from the Midlife Women's Health Study. Menopause 2015;22:1098–1107.
Ayers B, Smith M, Hellier J et al.. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial. Menopause 2012;19:749–759.
Alder J, Eymann Besken K, Armbruster U et al.. Cognitive-behavioural group intervention for climacteric syndrome. Psychother Psychosom 2006;75:298–303.
Mann E, Smith MJ, Hellier J et al.. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol 2012;13:309–318.
Baber RJ, Panay N, Fenton AGroup IMSW. 2016 IMS recommendations on women's midlife health and menopause hormone therapy. Climacteric 2016;19:109–150.
Barnabei VM, Grady D, Stovall DW et al.. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002;100:1209–1218.
Brunner RL, Aragaki A, Barnabei V et al.. Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. Menopause 2010;17:946–954.
de Villiers TJ, Hall JE, Pinkerton JV et al.. Revised global consensus statement on menopausal hormone therapy. Climacteric 2016;19:313–315.
Greendale GA, Reboussin BA, Hogan P et al.. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998;92:982–988.
Anderson GL, Limacher M, Assaf AR et al.. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–1712.
Rossouw JE, Anderson GL, Prentice RL et al.. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–333.
Chlebowski RT, Wactawski-Wende J, Ritenbaugh C et al.. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004;350:991–1004.
Chlebowski RT, Schwartz AG, Wakelee H et al.. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009;374:1243–1251.
Simon MS, Chlebowski RT, Wactawski-Wende J et al.. Estrogen plus progestin and colorectal cancer incidence and mortality. J Clin Oncol 2012;30:3983–3990.
Chlebowski RT, Anderson GL, Gass M et al.. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684–1692.
Chlebowski RT, Rohan TE, Manson JE et al.. Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 Women's Health Initiative randomized clinical trials. JAMA Oncol 2015;1:296–305.
Marjoribanks J, Farquhar C, Roberts H et al.. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2017;1:CD004143.
Barakat RR, Bundy BN, Spirtos NM et al.. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2006;24:587–592.
Chapman JA, DiSaia PJ, Osann K et al.. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996;175:1195–1200.
Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326–330.
Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990;36:189–191.
Suriano KA, McHale M, McLaren CE et al.. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 2001;97:555–560.
Holmberg L, Iversen OE, Rudenstam CM et al.. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008;100:475–482.
Fahlen M, Fornander T, Johansson H et al.. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 2013;49:52–59.
Bergendal A, Kieler H, Sundstrom A et al.. Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration. Menopause 2016;23:593–599.
Kagan R, Williams RS, Pan K et al.. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010;17:281–289.
American College of Obstetricians and Gynecologists Committee on Gynecologic Practice American Society for Reproductive Medicine Practice Committee. Compounded bioidentical menopausal hormone therapy. Fertil Steril 2012;98:308–312.
Whelan AM, Jurgens TM, Trinacty M. Bioidentical progesterone cream for menopause-related vasomotor symptoms: is it effective? Ann Pharmacother 2013;47:112–116.
Biglia N, Peano E, Sgandurra P et al.. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol 2010;26:404–412.
Sutton KS, Boyer SC, Goldfinger C et al.. To lube or not to lube: experiences and perceptions of lubricant use in women with and without dyspareunia. J Sex Med 2012;9:240–250.
Loprinzi CL, Abu-Ghazaleh S, Sloan JA et al.. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997;15:969–973.
Ayton RA, Darling GM, Murkies AL et al.. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol 1996;103:351–358.
- Search Google Scholar
- Export Citation
. Ayton RA Darling GM Murkies AL A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol 1996; 103: 351– 358.
Fooladi E, Davis SR. An update on the pharmacological management of female sexual dysfunction. Expert Opin Pharmacother 2012;13:2131–2142.
Raghunandan C, Agrawal S, Dubey P et al.. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J Sex Med 2010;7:1284–1290.
Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006:CD001500.
Committee Opinion No. 659 summary: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol 2016;127:618–619.
Le Ray I, Dell'Aniello S, Bonnetain F et al.. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat 2012;135:603–609.
Trinkaus M, Chin S, Wolfman W et al.. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 2008;13:222–231.
Wills S, Ravipati A, Venuturumilli P et al.. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract 2012;8:144–148.
- Search Google Scholar
- Export Citation
. Wills S Ravipati A Venuturumilli P Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract 2012; 8: 144– 148.
Barton DL, Sloan JA, Shuster LT et al.. Impact of vaginal dehydroepiandosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance) [abstract]. J Clin Oncol 2014;32(Suppl):Abstract 9507.
Mazzarello S, Hutton B, Ibrahim MF et al.. Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials. Breast Cancer Res Treat 2015;152:1–8.
Gerber GS, Zagaja GP, Ray PS, Rukstalis DB. Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology 2000;55:97–101.
Irani J, Salomon L, Oba R et al.. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol 2010;11:147–154.
- Search Google Scholar
- Export Citation
. Irani J Salomon L Oba R Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol 2010; 11: 147– 154.
Moraska AR, Atherton PJ, Szydlo DW et al.. Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB. J Support Oncol 2010;8:128–132.
Loprinzi CL, Dueck AC, Khoyratty BS et al.. A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol 2009;20:542–549.
Quella SK, Loprinzi CL, Sloan J et al.. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 1999;162:98–102.
Ashamalla H, Jiang ML, Guirguis A et al.. Acupuncture for the alleviation of hot flashes in men treated with androgen ablation therapy. Int J Radiat Oncol Biol Phys 2011;79:1358–1363.
Frisk J, Spetz AC, Hjertberg H et al.. Two modes of acupuncture as a treatment for hot flushes in men with prostate cancer—a prospective multicenter study with long-term follow-up. Eur Urol 2009;55:156–163.
Stefanopoulou E, Yousaf O, Grunfeld EA, Hunter MS. A randomised controlled trial of a brief cognitive behavioural intervention for men who have hot flushes following prostate cancer treatment (MANCAN). Psychooncology 2015;24:1159–1166.
Dueregger A, Heidegger I, Ofer P et al.. The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment. Nutrients 2014;6:4491–4519.
Klein EA, Thompson IM Jr, Tangen CM et al.. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011;306:1549–1556.
Peters U, Littman AJ, Kristal AR et al.. Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and Lifestyle (VITAL) study cohort. Cancer Causes Control 2008;19:75–87.
Bautista-Vidal C, Barnoiu O, Garcia-Galisteo E et al.. Treatment of gynecomastia in patients with prostate cancer and androgen deprivation. Actas Urol Esp 2014;38:34–40.
Viani GA, Bernardes da Silva LG, Stefano EJ. Prevention of gynecomastia and breast pain caused by androgen deprivation therapy in prostate cancer: tamoxifen or radiotherapy? Int J Radiat Oncol Biol Phys 2012;83:e519–524.
Jackson SE, Wardle J, Steptoe A, Fisher A. Sexuality after a cancer diagnosis: a population-based study. Cancer 2016;122:3883–3891.
Vomvas D, Iconomou G, Soubasi E et al.. Assessment of sexual function in patients with cancer undergoing radiotherapy—a single centre prospective study. Anticancer Res 2012;32:657–664.
Bober SL, Carter J, Falk S. Addressing female sexual function after cancer by internists and primary care providers. J Sex Med 2013;10(Suppl 1):112–119.
Forbat L, White I, Marshall-Lucette S, Kelly D. Discussing the sexual consequences of treatment in radiotherapy and urology consultations with couples affected by prostate cancer. BJU Int 2012;109:98–103.
Reese JB, Sorice K, Beach MC et al.. Patient-provider communication about sexual concerns in cancer: a systematic review. J Cancer Surviv 2017;11:175–188.
Sporn NJ, Smith KB, Pirl WF et al.. Sexual health communication between cancer survivors and providers: how frequently does it occur and which providers are preferred? Psychooncology 2015;24:1167–1173.
White ID, Allan H, Faithfull S. Assessment of treatment-induced female sexual morbidity in oncology: is this a part of routine medical follow-up after radical pelvic radiotherapy? Br J Cancer 2011;105:903–910.
Frumovitz M, Sun CC, Schover LR et al.. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 2005;23:7428–7436.
Ganz PA, Desmond KA, Belin TR et al.. Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 1999;17:2371–2380.
Ganz PA, Rowland JH, Desmond K et al.. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998;16:501–514.
Lindau ST, Gavrilova N, Anderson D. Sexual morbidity in very long term survivors of vaginal and cervical cancer: a comparison to national norms. Gynecol Oncol 2007;106:413–418.
Park SY, Bae DS, Nam JH et al.. Quality of life and sexual problems in disease-free survivors of cervical cancer compared with the general population. Cancer 2007;110:2716–2725.
Rodrigues AC, Teixeira R, Teixeira T et al.. Impact of pelvic radiotherapy on female sexuality. Arch Gynecol Obstet 2012;285:505–514.
Gershenson DM, Miller AM, Champion VL et al.. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study. J Clin Oncol 2007;25:2792–2797.
Lammerink EA, de Bock GH, Pras E et al.. Sexual functioning of cervical cancer survivors: a review with a female perspective. Maturitas 2012;72:296–304.
Fobair P, Stewart SL, Chang S et al.. Body image and sexual problems in young women with breast cancer. Psychooncology 2006;15:579–594.
Syrjala KL, Kurland BF, Abrams JR et al.. Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years. Blood 2008;111:989–996.
Thygesen KH, Schjodt I, Jarden M. The impact of hematopoietic stem cell transplantation on sexuality: a systematic review of the literature. Bone Marrow Transplant 2012;47:716–724.
Watson M, Wheatley K, Harrison GA et al.. Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial. Cancer 1999;86:1231–1239.
- Search Google Scholar
- Export Citation
. Watson M Wheatley K Harrison GA Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial. Cancer 1999; 86: 1231– 1239.
Zantomio D, Grigg AP, MacGregor L et al.. Female genital tract graft-versus-host disease: incidence, risk factors and recommendations for management. Bone Marrow Transplant 2006;38:567–572.
Montague DK, Jarow JP, Broderick GA et al.. Erectile Dysfunction. American Urological Association, 2005. Available at: http://www.auanet.org/education/guidelines/erectile-dysfunction.cfm. Accessed May 3, 2017.
Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. Int J Impot Res 2005;17:307–319.
Monga M, Bettencourt R, Barrett-Connor E. Community-based study of erectile dysfunction and sildenafil use: the Rancho Bernardo study. Urology 2002;59:753–757.
Ellis R, Smith A, Wilson S et al.. The prevalence of erectile dysfunction in post-treatment colorectal cancer patients and their interests in seeking treatment: a cross-sectional survey in the west-midlands. J Sex Med 2010;7:1488–1496.
Hendren SK, O'Connor BI, Liu M et al.. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg 2005;242:212–223.
Potosky AL, Davis WW, Hoffman RM et al.. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004;96:1358–1367.
Resnick MJ, Koyama T, Fan KH et al.. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013;368:436–445.
Schover LR, Fouladi RT, Warneke CL et al.. Defining sexual outcomes after treatment for localized prostate carcinoma. Cancer 2002;95:1773–1785.
Siegel T, Moul JW, Spevak M et al.. The development of erectile dysfunction in men treated for prostate cancer. J Urol 2001;165:430–435.
Stanford JL, Feng Z, Hamilton AS et al.. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000;283:354–360.
Loren AW, Mangu PB, Beck LN et al.. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2500–2510.
Armuand GM, Wettergren L, Rodriguez-Wallberg KA, Lampic C. Desire for children, difficulties achieving a pregnancy, and infertility distress 3 to 7 years after cancer diagnosis. Support Care Cancer 2014;22:2805–2812.
Murphy D, Orgel E, Termuhlen A et al.. Why healthcare providers should focus on the fertility of AYA cancer survivors: it's not too late! Front Oncol 2013;3:248.
Quinn MM, Letourneau JM, Rosen MP. Contraception after cancer treatment: describing methods, counseling, and unintended pregnancy risk. Contraception 2014;89:466–471.
Bartula I, Sherman KA. Development and validation of the Female Sexual Function Index adaptation for breast cancer patients (FSFI-BC). Breast Cancer Res Treat 2015;152:477–488.
Hatzichristou D, Rosen RC, Derogatis LR et al.. Recommendations for the clinical evaluation of men and women with sexual dysfunction. J Sex Med 2010;7:337–348.
McGahuey CA, Gelenberg AJ, Laukes CA et al.. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25–40.
Rosen R, Brown C, Heiman J et al.. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191–208.
Abraham L, Symonds T, Morris MF. Psychometric validation of a sexual quality of life questionnaire for use in men with premature ejaculation or erectile dysfunction. J Sex Med 2008;5:595–601.
Baser RE, Li Y, Carter J. Psychometric validation of the Female Sexual Function Index (FSFI) in cancer survivors. Cancer 2012;118:4606–4618.
Jeffery DD, Tzeng JP, Keefe FJ et al.. Initial report of the cancer Patient-Reported Outcomes Measurement Information System (PROMIS) sexual function committee: review of sexual function measures and domains used in oncology. Cancer 2009;115:1142–1153.
Bartula I, Sherman KA. Screening for sexual dysfunction in women diagnosed with breast cancer: systematic review and recommendations. Breast Cancer Res Treat 2013;141:173–185.
Flynn P, Kew F, Kisely SR. Interventions for psychosexual dysfunction in women treated for gynaecological malignancy. Cochrane Database Syst Rev 2009:CD004708.
Brotto LA, Erskine Y, Carey M et al.. A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer. Gynecol Oncol 2012;125:320–325.
Hummel SB, van Lankveld JJ, Oldenburg HS et al.. Efficacy of internet-based cognitive behavioral therapy in improving sexual functioning of breast cancer survivors: results of a randomized controlled trial. J Clin Oncol 2017;35:1328–1340.
Hickey M, Marino JL, Braat S, Wong S. A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer. Breast Cancer Res Treat 2016.
Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol 2015;33:3394–3400.
Yang EJ, Lim JY, Rah UW, Kim YB. Effect of a pelvic floor muscle training program on gynecologic cancer survivors with pelvic floor dysfunction: a randomized controlled trial. Gynecol Oncol 2012;125:705–711.
Miles T, Johnson N. Vaginal dilator therapy for women receiving pelvic radiotherapy. Cochrane Database Syst Rev 2010:CD007291.
Melisko ME, Goldman ME, Hwang J et al.. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncol 2017;3:313–319.
Archer DF, Labrie F, Bouchard C et al.. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause 2015;22:950–963.
Archer DF, Labrie F, Montesino M, Martel C. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10mcg estradiol on symptoms of vulvovaginal atrophy. J Steroid Biochem Mol Biol 2017, pii: S0960-0760(17)30079-1.
Labrie F, Archer DF, Bouchard C et al.. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric 2011;14:282–288.
Labrie F, Archer DF, Koltun W et al.. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 2016;23:243–256.
Labrie F, Archer DF, Bouchard C et al.. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas 2015;81:46–56.
Scheffers CS, Armstrong S, Cantineau AE et al.. Dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane Database Syst Rev 2015;1:CD011066.
INTRAROSA (prasterone) vaginal inserts. Shionogi Inc.; 2016. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208470s000lbl.pdf. Accessed April 28, 2017.
OSPHENA (ospemifene). Shionogi Inc.; 2015. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203505s005lbl.pdf. Accessed May 3, 2017.
Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010;17:480–486.
Goldstein SR, Bachmann GA, Koninckx PR et al.. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 2014;17:173–182.
Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013;20:623–630.
ADDYI (flibanserin). Sprout Pharmaceuticals, Inc.; 2015. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf. Accessed May 3, 2017.
Jaspers L, Feys F, Bramer WM et al.. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med 2016;176:453–462.
Gao Z, Yang D, Yu L, Cui Y. Efficacy and safety of flibanserin in women with hypoactive sexual desire disorder: a systematic review and meta-analysis. J Sex Med 2015;12:2095–2104.
Goldstein I, Kim NN, Clayton AH et al.. Hypoactive sexual desire disorder: International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. Mayo Clin Proc 2017;92:114–128.
Segraves RT, Croft H, Kavoussi R et al.. Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women. J Sex Marital Ther 2001;27:303–316.
Segraves RT, Clayton A, Croft H et al.. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J Clin Psychopharmacol 2004;24:339–342.
Landen M, Eriksson E, Agren H, Fahlen T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1999;19:268–271.
Cavalcanti AL, Bagnoli VR, Fonseca AM et al.. Effect of sildenafil on clitoral blood flow and sexual response in postmenopausal women with orgasmic dysfunction. Int J Gynaecol Obstet 2008;102:115–119.
Yang CC, Cao YY, Guan QY et al.. Influence of PDE5 inhibitor on MRI measurement of clitoral volume response in women with FSAD: a feasibility study of a potential technique for evaluating drug response. Int J Impot Res 2008;20:105–110.
Alexander MS, Rosen RC, Steinberg S et al.. Sildenafil in women with sexual arousal disorder following spinal cord injury. Spinal Cord 2011;49:273–279.
Basson R, McInnes R, Smith MD et al.. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002;11:367–377.
Basson R, Brotto LA. Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomised controlled trial. BJOG 2003;110:1014–1024.
Berman JR, Berman LA, Toler SM et al.. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. J Urol 2003;170:2333–2338.
Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. BJOG 2001;108:623–628.
Caruso S, Rugolo S, Agnello C et al.. Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study. Fertil Steril 2006;85:1496–1501.
Esposito K, Giugliano F, Di Palo C et al.. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004;291:2978–2984.
Lamina S, Okoye CG, Dagogo TT. Therapeutic effect of an interval exercise training program in the management of erectile dysfunction in hypertensive patients. J Clin Hypertens (Greenwich) 2009;11:125–129.
Khoo J, Piantadosi C, Duncan R et al.. Comparing effects of a low-energy diet and a high-protein low-fat diet on sexual and endothelial function, urinary tract symptoms, and inflammation in obese diabetic men. J Sex Med 2011;8:2868–2875.
Khoo J, Piantadosi C, Worthley S, Wittert GA. Effects of a low-energy diet on sexual function and lower urinary tract symptoms in obese men. Int J Obes (Lond) 2010;34:1396–1403.
Maio G, Saraeb S, Marchiori A. Physical activity and PDE5 inhibitors in the treatment of erectile dysfunction: results of a randomized controlled study. J Sex Med 2010;7:2201–2208.
Andersson E, Walen C, Hallberg J et al.. A randomized controlled trial of guided Internet-delivered cognitive behavioral therapy for erectile dysfunction. J Sex Med 2011;8:2800–2809.
Aubin S, Heiman JR, Berger RE et al.. Comparing sildenafil alone vs. sildenafil plus brief couple sex therapy on erectile dysfunction and couples' sexual and marital quality of life: a pilot study. J Sex Marital Ther 2009;35:122–143.
Banner LL, Anderson RU. Integrated sildenafil and cognitive-behavior sex therapy for psychogenic erectile dysfunction: a pilot study. J Sex Med 2007;4:1117–1125.
Boddi V, Castellini G, Casale H et al.. An integrated approach with vardenafil orodispersible tablet and cognitive behavioral sex therapy for treatment of erectile dysfunction: a randomized controlled pilot study. Andrology 2015;3